B. Metzler seel. Sohn & Co. AG Has $1.46 Million Position in BioNTech SE Sponsored ADR $BNTX

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in BioNTech SE by 34.3% in the first quarter, now holding 16,066 shares valued at approximately $1.46 million.
• BioNTech's shares are currently trading down by 1.9%, with a market capitalization of $24.04 billion and a PE ratio of -62.50.
• Wall Street analysts hold a consensus rating of "Moderate Buy" for BioNTech, with target prices set between $112.00 and $155.00 from various research firms.

B. Metzler seel. Sohn & Co. AG raised its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 34.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,066 shares of the company's stock after acquiring an additional 4,107 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in BioNTech were worth $1,463,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BNTX. Banque Cantonale Vaudoise bought a new position in BioNTech in the first quarter valued at approximately $36,000. Costello Asset Management INC bought a new position in shares of BioNTech during the first quarter worth $91,000. Goodman Advisory Group LLC bought a new position in shares of BioNTech during the first quarter worth $105,000. Whittier Trust Co. boosted its position in shares of BioNTech by 3,846.2% during the first quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock worth $187,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of BioNTech by 61.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock worth $214,000 after purchasing an additional 713 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Up 3.1%

BNTX stock traded up $3.08 during midday trading on Thursday, hitting $103.50. The company's stock had a trading volume of 786,301 shares, compared to its average volume of 675,214. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $131.49. The company's fifty day moving average price is $109.37 and its 200 day moving average price is $104.60. The stock has a market capitalization of $24.88 billion, a P/E ratio of -64.69 and a beta of 1.39.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. During the same quarter in the previous year, the firm posted ($3.36) earnings per share. The firm's quarterly revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of recent analyst reports. Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday, June 2nd. The Goldman Sachs Group initiated coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target on the stock. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the stock an "overweight" rating in a research report on Tuesday, August 5th. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Finally, Morgan Stanley raised their price objective on shares of BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $135.80.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.